Effects of Travoprost on Neovascular Glaucoma

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00441181

Enrollment

Registered

2007-02-28

Start date

2008-01-31

Completion date

2008-12-31

Last updated

2011-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Glaucoma

Keywords

Neovascular glaucoma, Travoprost

Brief summary

Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma.

Interventions

DRUGTravoprost

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Neovascular glaucoma of known cause * Older than 18 years * Previously submitted to retinal photocoagulation * Under medical treatment to glaucoma

Exclusion criteria

* Need of antiglaucomatous surgery * Previous ocular surgery in the last 6 months * Pregnancy

Design outcomes

Primary

Measure	Time frame
Intraocular pressure	—

Secondary

Measure	Time frame
Inflammation	—

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026